Archive for the ‘cardiology retractions’ Category
One of the retracted papers in the Journal of Neurosurgery (JNS) had multiple problems that were “too extensive to revise,” according to the lengthy retraction notice, relating to issues with authorship, data analyses, and patient enrollment. The notice is signed by first author Hua Liu of the Nanjing Medical University in China.
Liu is also the first author of another recently retracted paper in Frontiers in Neuroscience, pulled for incorrectly categorizing patients.
A publisher in the Netherlands has retracted 13 published studies and withdrawn 52 that were under consideration (but not yet published) after learning that someone illegally accessed its workflows to add fake authors and manipulate text.
According to Seyyed Mohammad Miri, the founder, CEO, and managing director of Kowsar Publishing, the 13 retracted papers all included extra authors added by the same Internet Protocol (IP) address. Cyber police in Iran found the same IP address had also accessed the 52 other papers, which were in various stages of the publishing process (such as peer review) and not yet online, Miri told Retraction Watch.
Most of the authors on the 13 retracted papers are based in institutions in Iran; some were co-authors on the 58 retractions recently issued as part of a mass clean-up by publishers BioMed Central and Springer, citing fake reviews, adding inappropriate authors, and plagiarism.
Around six or seven months ago, the affected journals — in collaboration with Kowsar, their publisher — filed a court case in Tehran, Iran against this IP address, Miri said. Read the rest of this entry »
Researchers have retracted and replaced a 2014 paper in JAMA Internal Medicine after realizing a number of errors had affected the findings.
The authors note the mistakes do not have a significant impact on the overall proportion of heart patients who participated in cardiac rehab. However, a number of findings were affected, such as the difference in participation in cardiac rehab defined by race, and how the overall participation has changed throughout the years.
Therefore, JAMA Internal Medicine has published a lengthy notice of retraction and replacement, which explains the errors made in the original paper, and updated the first paper with a new version of the study.
The retraction notices, which appear in Clinical Science, mention investigations into the work of Kou-Gi Shyu at the Shin-Kong Wu Ho-Su Memorial Hospital and Taipei Medical University (TMU).
Shyu is listed as being affiliated with both institutions in the original papers, but a TMU official told us Shyu left his teaching role at TMU amidst the probe. Shyr-Yi Lin, professor of medicine and dean of research and development at TMU, noted: Read the rest of this entry »
A second paper about a major randomized trial in Japanese patients with heart disease is being retracted, after an investigation reportedly found multiple problems with the paper.
As predicted by Pharma Japan, Hypertension Research is retracting a 2011 paper, already the subject of two errata. Although a spokesperson said she couldn’t say why the paper was being retracted, as the notice was still in production, editor Toshihiko Ishimitsu told us: Read the rest of this entry »
A German district attorney has fined a doctor who participated in a bogus study showing chocolate helps weight loss, designed to illustrate how shady science can make the news, arguing it was unethical to ask people to participate unknowingly in such a scam.
As soon as the study was published, critics raised questions over whether it was appropriate to include volunteers in a bogus clinical trial, which included giving blood. Recently, a German district attorney for professional conduct of physicians ruled that it was not.
In an anonymized version of a decision from the district attorney – who investigates on possible violations of the physicians’ professional law – he fined the doctor who participated in a bogus study about the health benefits of chocolate 500 Euros for not obtaining proper consent from the people who volunteered to participate, and for not involving an ethics committee. Read the rest of this entry »
The Journal of the American College of Cardiology (JACC) has retracted a recently published paper that questioned the effectiveness of a treatment for irregular heartbeat, against the last author’s wishes.
Andrea Natale, the study’s last and corresponding author and Executive Medical Director of Texas Cardiac Arrhythmia at Austin, took to social media today to express his frustration in the retraction of the July paper, which showed electrical rotors were less effective at fixing irregular heartbeat than other treatments. On Twitter, Natale implied industry played a role in its demise.
However, according to the retraction notice, the paper was felled by problems with randomization; Natale has admitted that some patients were removed from the analysis after one center included them incorrectly.
Author lifts from one paper in two different articles. Why does one journal retract, while the other corrects?
Are there instances when similarities between papers should be fixed by a correction, rather than a retraction?
We’re asking ourselves that question after seeing two journals take very different approaches to a somewhat similar situation. Last year, Frontiers in Physiology retracted a paper by Anastasios Lymperopoulos at Nova Southeastern University in Florida because of an “an unacceptable level of similarity” to a 2009 review article by different authors. But more recently, after Circulation Research discovered another paper co-authored by Lymperopoulos also contained similar text from the same 2009 review, it decided to correct the passages.
The last author of the Circulation Research paper told us the overlap between the two papers was less than 5%, and the journal never suggested the authors retract the paper.
Here’s the correction notice in Circulation Research:
How is that possible? A spokesperson for Springer told us that they have reason to believe a third-party company may have helped prepare the papers for publication, and in the process might have spread the material around to multiple manuscripts.
The details of the cluster are a bit perplexing, so bear with us. Two of the papers — that were published only months apart — have already been retracted, as we reported in April. Now, two other papers have been retracted from Molecular Biology Reports — and both notices cite the previously retracted papers. The new notices also say that there’s reason to believe that the peer-review process was compromised.
All papers conclude that a certain polymorphism could signal a risk for coronary artery disease among Chinese people.
We’ll start with the retraction notice for “Fibroblast growth factor receptor 4 polymorphisms and coronary artery disease: a case control study,” which cites the two papers that were retracted previously:
PLOS ONE has retracted three papers after the first author admitted to submitting the manuscripts without co-authors’ consent, and an investigation suggested that two out of the three papers had received faked reviews.
Last August, the same author — Lishan Wang of the Shanghai Jiao Tong University — lost two more papers (one in Tumor Biology and the other in Gene), also after the peer review process was found to be compromised. All five papers — which share other authors in common — were originally published in 2013, and four list Wang as the first author. The retractions follow an investigation by Shanghai Jiao Tong University.